Identifying and reducing potentially wrong immunoassay results even when plausible and "not-unreasonable"

Advances in Clinical Chemistry

Volumn 66, Issue , 2014, Pages 241-294

  Ismail, Adel A A ^a  

^a PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

Conventional and bayesian statistics; Identifying wrong immunoassay results; Inaccuracy in immunoassays; Interference in immunoassays; Statistics in laboratory medicine; Wrong immunoassay results

Indexed keywords

ANTIGEN ANTIBODY REACTION; ARTICLE; BAYES THEOREM; DIAGNOSTIC ERROR; HUMAN; IMMUNOASSAY; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); METHODOLOGY;

ANTIGEN-ANTIBODY REACTIONS; BAYES THEOREM; DIAGNOSTIC ERRORS; HUMANS; IMMUNOASSAY; MEDICAL LABORATORY SCIENCE; META-ANALYSIS AS TOPIC;

EID: 84906078045     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801401-1.00007-4     Document Type: Chapter

References (175)

1. Bland J.M., Altman D.G. Bayesians and frequentists. BMJ 1998, 317:468-469.
2. Lindley D.V. The philosophy of statistics. Statistician 2000, 49:293-337.
3. Altman D.G., Bland J.M. Predictive values. BMJ 1994, 309:102.
4. Altman D.G., Bland J.M. Receiver operating characteristic plots. BMJ 1994, 309:188.
5. Jones R., Payne B. Clinical Investigations and Statistics in Laboratory Medicine 1997, ACB Venture Publications, London.
6. Bland J.M., Altman D.G. Transformations, means and confidence intervals. BMJ 1996, 312:1153.
7. Ioannidis J.P.A. Why most published research findings are false. PLoS Med. 2005, 2:124-128.
8. Westover M.B., Westover K.D., Bianchi M. Significance testing as perverse probabilistic reasoning. BMC Med. 2011, 9:20-27.
9. Lee P.M. Bayesian Statistics-An Introduction 2004, Wiley, Chichester, West Sussex. third ed.
10. Bolstad W.M. Introduction to Bayesian Statistics 2004, Wiley, Chichester.
11. Lunn D.J., Thomas A., Best N., Spiegelhalter D. A Bayesian modelling framework: concepts, structure and extensibility. Stat. Comput. 2000, 10:325-337.
12. Kass R.E., Wasserman L. The selection of prior distribution by formal rules. J. Am. Stat. Assoc. 1996, 91:1343-1370.
13. Berger J.O., Bernardo J.M., Sun D. The formal definition of reference priors. Ann. Stat. 2009, 37:905-938.
14. Fisher R.A. Statistical Methods for Research Workers 1925, Oliver and Boyd, Edinburgh.
15. Hubbard R., Lindsay R.M. Why P-values are not a useful measure of evidence in statistical significance testing. Theory Psychol. 2008, 18:69-88.
16. Berger J.O., Berry D.A. Statistical analysis and the illusion of objectivity. Am. Sci. 1988, 76:159-165.
17. Goodman S.P. Toward evidence-based medical statistics. 1: the p value fallacy. Ann. Intern. Med. 1999, 130:995-1004.
18. Goodman S.P. Toward evidence-based medicinal statistics. 2: the Bayes factor. Ann. Intern. Med. 1999, 130:1005-1013.
19. Bernardo J.M., Rueda R. Bayesian hypothesis testing. A reference approach. Int. Stat. Rev. 2002, 70:351-372.
20. Lilford R.J., Braunholtz D. The statistical basis of public policy: a paradigm shift is overdue. BMJ 1996, 313:603-607.
21. Glass G.V. Primary, secondary, and meta-analysis of research. Educ. Res. 1976, 5:3-8.
22. Spiegelhalter D.J., Abrams K.R., Myles J.P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation 2004, John Wiley & Sons, Chichester, West Sussex, England.
23. Higgins J.P.T., Spiegelhalter D.J. Being skeptical about meta-analysis: a Bayesian perspective on magnesium trials in myocardial infarction. Int. J. Epidemiol. 2002, 31:96-104.
24. Altman D.G. The time has come to register diagnostic and prognostic research. Clin. Chem. 2014, 60:508-512.
25. Korevaar D.A., Ochodo E.A., Bossuyt P.M.M., Hooft L. Publication and reporting of test accuracy studies in clinical trials.gov. Clin. Chem. 2014, 60:651-659.
26. Sutton A.J., Abrams K.R. Bayesian methods in meta-analysis and evidence synthesis. Stat. Methods Med. Res. 2001, 10:277-303.
27. Lewington S., Bragg F., Clarke R. A review on meta-analysis of biomarkers: promises and pitfalls. Clin. Chem. 2012, 58:1192-1204.
28. Aguinis H., Beaty J.C., Boik R.J., Pierce C.A. Effect of size and power in assessing moderating effects of categorical variables using multiple regression: a 30-year review. J. Appl. Psychol. 2005, 90:94-107.
29. Lipsey M.W. Those confounded moderators in meta-analysis: good, bad and ugly. Ann. Am. Acad. Pol. Soc. Sci. 2003, 587:169-181.
30. 131I metabolism in human subjects. Demonstration of insulin binding globulin of treated patients. J. Clin. Invest. 1956, 35:170-190.
31. Yalow R., Berson S. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 1960, 39:1157-1175.
32. Hunter W.M., Greenwood F.C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962, 194:495-496.
33. Miles L.E.M., Hales C.N. Labeled antibodies and immunological assay systems. Nature 1968, 219:186-189.
34. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predicted specificity. Nature 1975, 256:495-497.
35. Davis C. Introduction to immunoassay principles. The Immunoassay Handbook 2001, 30-31. Nature Publishing Group, London. D. Wild (Ed.).
36. Ismail A.A.A. Interference from endogenous antibodies in automated immunoassays: what laboratorians need to know. J. Clin. Pathol. 2009, 62:673-678.
37. Ismail A.A.A., Ismail A.A., Ismail Y. Probabilistic Bayesian reasoning can help identifying potentially wrong immunoassays results in clinical practice: even when they appear not-unreasonable. Ann. Clin. Biochem. 2011, 48:65-71.
38. Bjerner J., Bolstad N., Piehler A. Belief is only half the truth-or why screening for heterophilic antibody interference in certain assays makes double sense. Ann. Clin. Biochem. 2012, 49:381-386.
39. Chitarra V., Alzari P.M., Bentley G.A., et al. Three-dimensional structure of a heteroclitic antigen-antibody cross-reaction complex. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:7711-7715.
40. Voss E.W. Significance and properties of the autoanti-metatype immune response. Mol. Immunol. 1993, 30:949-951.
41. Braden B.C., Poljak R.J. Structural features of the reactions between antibodies and protein antigens. FASEB J. 1995, 9:9-16.
42. Wingren C., Hansson U.B., Magnusson C.G.M., et al. Antigen-binding sites dominate the surface properties of IgG antibodies. Mol. Immunol. 1995, 32:819-827.
43. Pan Y., Yuhasz S.C., Amzel L.M. Anti-idiotypic antibodies: biological function and structural studies. Exp. Biol. Med. J. 1995, 9:43-49.
44. Fields B.A., Goldbaum F.A., Ysem X., et al. Molecular basis of antigen mimicry by antiidiotope. Nature 1995, 374:739-742.
45. Kramer A., Keitel T., Winkler K., et al. Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 1997, 91:799-809.
46. Weir D.M., Stewart J. Antigens and antigen recognition. Immunology 1997, 69-80. Churchill Livingstone, Edinburgh. D.M. Weir (Ed.).
47. Ismail A.A.A., Walker P.L., Cawood M.L., Barth J.H. Interference in immunoassay is an underestimated problem. Ann. Clin. Biochem. 2002, 39:366-373.
48. Rini J.M., Schulze-Gahmen U., Wilson I.A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992, 255:959-965.
49. Bosshard H.R. Molecular recognition by induced fit: how fit is the concept. News Physiol. Sci. 2001, 16:171-177.
50. Rodbard D., Feldman F.A. Theorem of protein ligand interaction. Methods Enzymol. 1975, 36:3-16.
51. Feldman H.A. Theorem of protein ligand interaction. Methods Enzymol. 1975, 36:3-16.
52. Holleman H.J.G., Bertina R.M. Scatchard plot and heterogeneity in binding affinity of labeled and unlabeled ligand. Clin. Chem. 1975, 21:1769-1773.
53. Ekins R.P. Assay design and quality control. Radioimmunoassay 1979, 239-255. Elsevier, Amsterdam. C.A. Bizallon (Ed.).
54. Ismail A.A.A., Walker P.L., Fahie-Wilson M.N., Jassam N., Barth J.H. Prolactin and macroprolactin: a case report on hyperprolactinaemia highlighting the interpretation of discrepant results. Ann. Clin. Biochem. 2003, 40:298-300.
55. Michielsen E.C., Bisschops P.G., Janssen M.J. False positive troponin result caused by a true macrotroponin. Clin. Chem. Lab. Med. 2011, 49:923-925.
56. Chen T., Hedman L., Mattila P.S., Jartti T., Ruuskanen O., Soderlund-Venermo M., Hedman K. Biotin IgM antibodies in human blood: a previously unknown factor eliciting false results in biotinylation-based immunoassays. PLoS One 2012, 7:e423-e426.
57. Plebani M., Mion M., Altinier S., et al. False positive troponin I attributed to a macrocomplex. Clin. Chem. 2002, 48:677-678.
58. Valdes R., Jortani S.A. Unexpected suppression of immunoassay results by crossreactivity: now a demonstrated cause for concern. Clin. Chem. 2002, 48:405-406.
59. Butler J. Negative interference in immunoassays. Clin. Chem. 1995, 41:481-482.
60. Ismail Y., Ismail A.A., Ismail A.A. Erroneous laboratory results: what clinicians need to know. Clin. Med. 2007, 7:357-361.
61. Sturgeon C.M., Viljoen A. Analytical error and interference in immunoassays: minimizing the risk. Ann. Clin. Biochem. 2011, 48:418-432.
62. Boerman O.C., Segers M.F., Poels L.C., et al. Heterophilic antibodies in human sera causing falsely increased results in CA-125 immunofluorimetric assay. Clin. Chem. 1990, 36:888-891.
63. O'Reilly S.M., Rustin G.J.S. Mismanagement of choriocarcinoma due to false low hCG measurement. Int. J. Gynecol. Cancer 1993, 3:186-188.
64. Bohner J., von Pape K.W., Hannes W., et al. False negative immunoassay result for cardiac troponin I probably due to circulating troponin I antibodies. Clin. Chem. 1996, 42:2046-2049.
65. Norden A.G.W., Jackson R.A., Norden L.E., et al. Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin. Chem. 1997, 43:957-962.
66. Fitzmaurice T.F., Brown C., Rifai N., et al. False increase of cardiac troponin I with heterophilic antibodies. Clin. Chem. 1998, 44:2212-2214.
67. Jones R.G., Barth J.H., Mitchell H. Tumour markers: same marker, different assay, different result. Clin. Oncol. 1999, 11:221-222.
68. Cole L.A., Rinne K.M., Shahabi S., et al. False-positive hCG assay results leading to unnecessary surgery and chemotherapy and needless occurrences of diabetes and coma. Clin. Chem. 1999, 45:313-314.
69. Krahn J., Parry D.M., Leroux M., et al. High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. Clin. Biochem. 1999, 32:477-480.
70. Rotmensch S., Cole L.A. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000, 355:712-715.
71. Kilpatrick E.S., Pell A.C., Pell J.P. Was it a heart attack?. BMJ 2002, 324:1216.
72. White G.H., Tideman P.A., Mangold D., et al. Heterophilic antibody interference with cardiac T Quantitative Rapid Assay-representatives of Roche Diagnostics respond. Clin. Chem. 2002, 48:201-203.
73. Preissner C.M., O'Kane D.J., Singh R., et al. Phantoms in the assay tube: heterophilic antibody interference in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 2003, 88:3069-3074.
74. Eriksson S., Junikka M., Laitinen P., et al. Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin. Chem. 2003, 49:1095-1104.
75. Bertalot G., Montresor G., Tampieri M., et al. Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin. Endocrinol. (Oxf.) 2004, 61:650-652.
76. Eriksson S., Halenius H., Pulkki K., et al. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin. Chem. 2005, 51:839-847.
77. Bolland M.J., Chiu W.W., Davidson J.S., et al. Heterophilic antibodies may cause falsely lowered serum cortisol values. J. Endocrinol. Invest. 2005, 28:643-645.
78. Saiegh L., Odeh M., Chen-Konak L., Elias N., Sheik-Ahmed M., Reut M., Slobodin G., Bejar J., Shechner C. A possible analytical and clinical role of endogenous antibodies causing discrepant adrenocorticotropic hormone measurement in a case of ectopic Cushing's syndrome. Ann. Clin. Biochem. 2014, 51:490-494.
79. Levinson S.S. Antibody multi-specificity in immunoassay interference. Clin. Biochem. 1992, 25:77-87.
80. Weber T.H., Käpyaho K.I., Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand. J. Clin. Lab. Invest. 1990, 50(Suppl. 201):77-82.
81. Koper N.P., Massuger L.F.A.G., Thomas C.M.G., Beyer C., Crooy M.J. An illustration of the clinical relevance of detecting human antimouse antibody interference by affinity chromatography. Eur. J. Obstet. Gynecol. Reprod. Biol. 1999, 86:203-205.
82. Sjowall C., Kastbom A., Almroth G., Wettero J., Skogh T. Beware of antibodies to dietary protein in "antigen-specific" immunoassays! Falsely positive anticytokine antibodies tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J. Rheumatol. 2011, 38:215-220.
83. Tuckova L., Tlaskalova-Hagenova H., Farre M., Karska K., Rossmann P., Kolinska J., et al. Molecular mimicry as a possible cause of autoimmune reactions in coeliac disease? Antibodies to gliaden cross-react with epitopes on enterocytes. Clin. Immunol. Immunopathol. 1995, 74:170-176.
84. Ismail A.A.A., Walker P.L., Barth J.H., Lewandowski C., Jones R., Burr W.A. Wrong biochemistry results: two case reports and observational study on 5310 patients on potentially misleading thyroid stimulating hormone and gonadotropin immunoassay results. Clin. Chem. 2002, 48:2023-2029.
85. Mills F., Jeffery J., Mackenzie P., Cranfield A., Ayling R.M. An immunoglobulin G complexed form of thyroid-stimulating hormone (macro thyroid-stimulating hormone) is a cause of elevated serum thyroid-stimulating hormone concentration. Ann. Clin. Biochem. 2013, 50:416-420.
86. Sosolik R.C., Hitchcock C.L., Becker W.J. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Am. J. Clin. Pathol. 1997, 107:506-510.
87. Losman M.J., Novick K.E., Goldenberg D.M., Monestier M. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. Int. J. Cancer 1994, 56:580-584.
88. Reinsberg J. Interferences with two-site immunoassays by human anti-mouse antibodies formed by patients treated with monoclonal antibodies: comparison of different blocking agents. Clin. Chem. 1998, 44:1742-1744.
89. Russell E., Zeihen M., Wergin S., Litton M.T. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum. 2000, 43:944.
90. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 2000, 355:735-740.
91. Arano Y. Delivery of diagnostic agents for gamma-imaging. Adv. Drug Deliv. Rev. 1999, 37:103-120.
92. Subbiah K., Myleru U., Anathananayanah M. Preliminary study on immunoscintigraphy of murine lymphoma using technetium-99M labelled chicken antibody. Tumouri 2000, 19:233-237.
93. Kricka L.J. Human anti-animal antibody interference in immunological assays. Clin. Chem. 1999, 45:942-956.
94. Schneider-Mergener J., Kramer A., Reineke U. Peptide libraries bound to continuous cellulose membranes: tools to study molecular recognition. Combinational Librarie 1996, 53-68. W de Gruyter, Berlin. R. Cotese (Ed.).
95. Bona C.A. Internal image concept revisited. Exp. Biol. Med. 1996, 213:32-42.
96. Voss E.W., Miklasz S.D., Petrossian A., Dombrink-Kurtzman M.A. Polyclonal antibodies specific for liganded active site (metatype) of a high affinity antihapten monoclonal antibody. Mol. Immunol. 1988, 25:751-759.
97. Weidner K.M., Denzin L.K., Voss E.W. Molecular stabilization effects of interactions between anti-metatype antibodies and liganded antibody. J. Biol. Chem. 1992, 267:10281-10288.
98. Oldstone M.B.A. Molecular mimicry and autoimmune disease. Cell 1987, 50:819-820.
99. Ismail A.A.A. A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. Clin. Chem. 2005, 51:25-26.
100. Jassam N.F., Ismail A.A.A., Cawood M., et al. Validation of PEG as a pre-analytical step for immunoassay of AFP, FSH and prolactin 2003, 82.
101. Ingham K.C. Polyethylene glycol in aqueous solution: solvent perturbation and gel filtration studies. Arch. Biochem. Biophys. 1977, 184:59-68.
102. Ingham K.C. Precipitation of proteins with polyethylene glycol. Methods Enzymol. 1990, 182:301-306.
103. Donald H., Atha D.H., Ingham K.C. Mechanism of precipitation of proteins by polyethylene glycols. Analysis in terms of excluded volume. J. Biol. Chem. 1981, 256:12108-12117.
104. Poslon A. A theory for the displacement of proteins and viruses with polyethylene glycol. Prep. Biochem. 1977, 79:129-154.
105. Ingham K.C. Precipitation of proteins with polyethylene glycol: characterization of albumin. Arch. Biochem. Biophys. 1978, 186:106-113.
106. Bjerner J., Børmer O.P., Nustad K. The war on heterophilic antibody interference. Clin. Chem. 2005, 51:9-11.
107. Carpenter B. Heterophile antibodies. Manual of Clinical Laboratory Immunology 1992, 6-8. American Society for Microbiology, Washington DC. fourth ed. N.R. Rose, E.C. de Macario, J.L. Fahey (Eds.).
108. Pretorius C.J., Dimeski G., O'Rourke P.K., Marquart L., Tyack S.A., Wilgen U., Ungerer P.J. Outliers as a cause of false cardiac troponin results: investigating the robustness of 4 contemporary assays. Clin. Chem. 2011, 57:710-718.
109. Wesolowski L.G., Delaney K.P., Lampe M.A., Nesheim S.R. False-positive human immunodeficiency virus enzyme immunoassay results in pregnant women. PLoS One 2011, 6:e1638-e1641.
110. Ismail A.A.A. On the diagnosis of subclinical hypothyroidism. Br. J. Gen. Pract. 2007, 57:1000-1001.
111. Ismail A.A.A. Thyroid stimulating hormone cut-off to define subclinical hypothyroidism. Ann. Clin. Biochem. 2009, 46:426.
112. Leey J., Cryer P. Discrepant thyroid function test in a 44-year old man. Clin. Chem. 2013, 59:1703-1707.
113. Smith C.V., Bauer J.J., Connelly R.R., et al. Prostate cancer in men age 50 years or younger: a review of the department of defense center for prostate disease multicenter database. J. Urol. 2000, 164:1964-1967.
114. Stark J.R. Screening for prostatic cancer remains controversial. BMJ 2009, 339:b3601.
115. Holmstrom B., Johansson M., Bergh A., Stenman U.F., Hallmans G., Stattin P. Prostate specific antigen for early detection of prostate cancer. BMJ 2009, 339:b3537.
116. Dragan I., Green S. Prostate specific antigen for detecting early prostate cancer. BMJ 2009, 339:b3572.
117. Hoffman R.M. Screening for prostate cancer. N. Eng. J. Med. 2011, 365:2013-2019.
118. Schroeder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomised European study. N. Eng. J. Med. 2009, 360:1320-1328.
119. Ismail A.A.A. On the interpretation of affirmative follow up tests in immunoassays: what must not done?. Ann. Clin. Biochem. 2006, 43:249-251.
120. Ismail A.A.A. On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test. Clin. Chem. Lab. Med. 2007, 45:851-854.
121. Javadpour N., Soares T. False-positive and false-negative alpha-fetoprotein and human chorionic gonadotropin assays in testicular cancer: a double blind study. Cancer 1981, 48:2279-2281.
122. Torjesen P.A., Bjero T. Antibodies against 125I testosterone in patient's serum. A problem for the laboratory and the patient. Clin. Chem. 1996, 42:2047-2048.
123. Cawood M.L., Field H.P., Ford C.G., Gillingwater S., Kicman A., Cowan D., Barth J.H. Testosterone measurement by isotope-dilution liquid chromatography tandem mass spectrometry: validation of a method for routine clinical practice. Clin. Chem. 2005, 51:1472-1479.
124. Kricka L.J. Commentary. Clin. Chem. 2008, 54:7.
125. Kricka L.J. Interference in immunoassays-still a threat. Clin. Chem. 2000, 46:1037-1038.
126. Legendre-Bazydlo L.A., Haverstick D.M., Kennedy J.L.W., Dent J.M., Burns D.E. Persistent increase in cardiac troponin I in plasma without evidence of cardiac injury. Clin. Chem. 2010, 56:702-705.
127. Adamczyk M., Brashear J., Mattingly P.G. Coprevalence of autoantibodies to cardiac troponin I and T in normal blood donors. Clin. Chem. 2010, 56:676-677.
128. Alp N.J., Bell J.A., Shahi M. A rapid troponin-I based protocol for assessing acute chest pain. Q. J. Med. 2001, 94:687-694.
129. Almasri A.A., Ababneh B.M. Role of troponin T and I in acute myocardial infarction. J. Coll. Physicians Surg. Pak. 2005, 15:170-178.
130. Jishi F., Hudson P.R., Williams C.P., et al. Troponin I, laboratory issues, and clinical outcomes in a district general hospital: crossover study with traditional markers of myocardial infarction of a total of 1990 patients. J. Clin. Pathol. 2004, 57:1027-1032.
131. Eriksson S., Junikka M., Petterson K. An interfering component in cardiac troponin I immunoassays-its nature and inhibiting effect on the binding of autoantibodies against different epitopes. Clin. Biochem. 2004, 37:472-480.
132. Eriksson S., Ilva T., Becker C., Lund J., Porela P., Pullki K. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin. Chem. 2005, 51:848-855.
133. Pettersson K., Eriksson S., Wittfooth S., Engstrom E., Nieminen M., Sinisalo J. Autoantibodies to cardiac troponin associate with higher initial concentration and longer release of troponin I in acute coronary syndrome patients. Clin. Chem. 2009, 55:938-945.
134. Savukoskl T., Engstrom E., Engblom J., Ristinleml A., Wittfooth S., Lindahl B., Eggers K.M., Venge P., Pettersson K. Troponin-specific autoantibody interference in different cardiac troponin I assay configurations. Clin. Chem. 2012, 58:1040-1048.
135. Keller T., Zeller T., Peetz D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Eng. J. Med. 2009, 361:868-877.
136. Marks V. Spontaneous hypoglycemia. Clin. Biochem. 2001, 3:67-71.
137. Ismail A.A.A. The double whammy of endogenous antibodies in non-diabetic subjects. Clin. Chem. Lab. Med. 2008, 46:153-156.
138. Elias D., Cohen I.R., Schechter Y., Spirer Z. Antibodies to insulin receptor followed by antibodies to insulin in child with hypoglycemia. Diabetes 1987, 36:348-354.
139. Basu A., Service F.J., Yu L., Heser D., Ferries L.M., Eisenbarth G. Insulin autoimmunity and hypoglycemia in seven white patients. Endocr. Pract. 2005, 11:97-103.
140. Bortolotti D., Mothe-Satney I., Ferrari P., et al. Spontaneous hypoglycaemia in the presence of both anti-insulin antibody and anti-insulin receptor antibody. Diabetes Metab. 2006, 32:598-603.
141. Lohmann T., Kratzsch J., Kellner K., Witzigmann H., Hauss J., Paschker R. Severe hypoglycemia due to insulin autoimmune syndrome with insulin autoantibodies crossreactive to proinsulin. Exp. Clin. Endocrinol. Diabetes 2001, 109:245-248.
142. Kato T., Itoh M., Hanashita J., et al. Severe hypoglycaemia in a person with insulin autoimmune syndrome accompanied by insulin receptor anomaly type B. Diabet. Med. 2007, 24:1279-1281.
143. Ismail A.A.A. Testing for insulin antibodies is mandatory in the differential diagnosis of hypoglycaemia in non-diabetic subjects. Clin. Endocrinol. 2012, 76:603-604.
144. Ismail A.A.A., Barth J.H. Wrong biochemistry results. BMJ 2001, 323:705-706.
145. Altman D.G., Bland J.M. Measurement in medicine: the analysis of method comparison studies. Statistician 1983, 32:307-317.
146. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
147. Stöckl D., Rodríguez Cabaleiro D., Van Uytfanghe K., Thienpont L.M. Interpreting method comparison studies by use of the Bland-Altman plot: reflecting the importance of sample size by incorporating confidence limits and predefined error limits in the graphic. Clin. Chem. 2004, 50:2216-2218.
148. Covinsky M., Laterza O., Pfeifer J.D., Farkas-Stallasi T., Scott M.G. An IgM l antibody to Escherichia coli produces false positive results in multiple immunometric assays. Clin. Chem. 2000, 46:1157-1161.
149. Scatchard G. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 1949, 51:660-672.
150. Walker W.H. An approach to immunoassay. Clin. Chem. 1977, 23:334-402.
151. Holleman H.J., Bertina R.M. Scatchard plot and heterogeneity in binding affinity of labeled and unlabelled ligand. Clin. Chem. 1975, 21:1769-1773.
152. Bjerner J., Nustad K., Norum L.F., Olsen K.H., Bomer O.P. Immunometric assay interference: incidence and prevention. Clin. Chem. 2002, 48:613-621.
153. Plebani M. What information on quality specification should be communicated to clinicians, and how?. Clin. Chem. Acta 2004, 346:25-35.
154. Fraser C.G. Biological Variation: From Principles to Practice 2001, AACC Press, Washington. sixth ed.
155. Roraas T., Petersen P.H., Sandberg S. Confidence intervals and power calculations for within-person biological variation: effect of analytical imprecision, number of replicates, number of samples and number of individuals. Clin. Chem. 2012, 58:1306-1313.
156. Pepe M.S., Fan J., Seymour C.W., Li C., Huang Y., Feng Z. Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin. Chem. 2012, 58:1242-1251.
157. Linnet K., Bossuyt P.M., Moons K.G., Reitsma J.B. Quantifying the accuracy of a diagnostic test or marker. Clin. Chem. 2012, 58:1292-1301.
158. Feng F., Sales A.P., Kepler T.B. A Bayesian approach for estimating calibration curves and unknown concentrations in immunoassays. Bioinformatics 2011, 27:707-712.
159. Emerson J.F., Ngo G., Emerson S.S. Screening for interference in immunoassays. Clin. Chem. 2003, 49:1163-1169.
160. Webster R., Fahie-Wilson M., Baker P., Chatterjee V.K., Halsall D.J. Immunoglobulin interference in serum follicle-stimulating hormone assays: autoimmune and heterophilic antibody interference. Ann. Clin. Biochem. 2010, 47:386-389.
161. Tate J., Ward G. Interference in immunoassays. Clin. Biochem. Rev. 2004, 25:105-120.
162. Bonetti A., Monica C., Bonaguri C., et al. Interference by heterophilic antibodies in immunoassays: wrong increase of myoglobin values. Acta Biomed. 2008, 79:140-143.
163. Giovaneolla L., Ghelfo A. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. Clin. Chem. 2007, 53:1871-1872.
164. Ross H.A., Menheere P.P.C.A., Thomas C.M.G., Mudde A.H., Kouwenberg M., Wolffenbuttel B.H.R. Interference from heterophilic antibodies in seven current TSH assays. Ann. Clin. Biochem. 2008, 45:616-618.
165. Heijboer A.C., Ijzerman R.G., Bouman A.A., Blankenstein M.A. Two cases of antiruthenium antibody interference in modular free thyroxine assay. Ann. Clin. Biochem. 2009, 46:263-264.
166. Span P.N., Grebenchtchikov N.J., Geurts-Moespot J., et al. Screening for interference in immunoassays. Clin. Chem. 2003, 49:1708-1709.
167. Zhi Z.L., Morita Y., Hasan Q., Tamiya E. Micromachining microcarrier-based bimolecular encoding for miniaturized and multiplexed immunoassay. Anal. Chem. 2003, 75:4125-4131.
168. Zhao Y.J., Zhoa X.W., Sun C., Li J., Zhu R., Gu Z.Z. Encoded silica colloidal crystal beads as supports for potential multiplex immunoassay. Anal. Chem. 2008, 80:1598-1605.
169. Cryer P.E., Axelrod L., Grossman A.B., Heller S.R., Montori V.M., Seaquist E.R., Service F.J. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2009, 94:709-728.
170. Diamandis E.P. Immunoassay interference: a relatively rare but still important problem. Clin. Biochem. 2004, 37:331-332.
171. Leape L.L. Striving for perfection. Clin. Chem. 2002, 48:1871-1872.
172. Gill C.J., Sabin L., Schmid C.H. Why clinicians are natural Bayesians. BMJ 2005, 330:1080-1083.
173. Plebani M. The future of clinical laboratories: more testing or knowledge service. Clin. Chem. Lab. Med. 2005, 43:893-896.
174. Bossuyt X., Verweire K., Blanckaert N. Laboratory medicine: challenges and opportunities. Clin. Chem. 2007, 53:1730-1733.
175. Plebani M., Lippi G. Is laboratory medicine a dying profession? Blessed are those who have not seen and yet have believed. Clin. Biochem. 2010, 43:939-941.